Dalantercept: Interim Phase II data

Interim data from an open-label, U.S. Phase II trial evaluating Acceleron's dalantercept as monotherapy in patients with recurrent or persistent epithelial ovarian cancer showed that 6 of 30 patients were progression free without receiving non-protocol therapy for >6 months. The trial design required >=7 of 30 patients to be progression free for >6 months at the interim analysis to trigger enrollment of an additional 30 patients in part 2 of the trial. Based on the data, part 2 of the trial will not enroll. The trial was sponsored by the Gynecologic Oncology Group. ...